NCT07154810 is a clinical trial in Glaucoma, sponsored by SpyGlass Pharma, Inc..

Who is sponsoring NCT07154810?

NCT07154810 is sponsored by SpyGlass Pharma, Inc..

What condition does NCT07154810 study?

NCT07154810 studies Glaucoma, Cataract, Ocular Hypertension.

Is NCT07154810 still recruiting?

NCT07154810 is currently active, enrolled. Last updated 4 September 2025.

Last reviewed 2025-09-04 · How we verify

NCT07154810

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Observational Study to Evaluate Long Term Outcomes for Ocular Hypertension and Glaucoma Patients Treated With the SpyGlass Bimatoprost Implant System / IOL Combination

Active, enrolled Last updated 4 September 2025

What this trial tests

trial in Glaucoma in 23 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

16 March 2023

Primary endpoint
14 April 2031

14 April 2031

Quick facts

Lead sponsor	SpyGlass Pharma, Inc.
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	23
Start date	16 March 2023
Primary completion	14 April 2031
Estimated completion	14 April 2031
Sites	1 location across Honduras

Conditions studied

Glaucoma — all drugs for Glaucoma →
Cataract — all drugs for Cataract →
Ocular Hypertension — all drugs for Ocular Hypertension →

Sponsor

SpyGlass Pharma, Inc. — full company profile →

Who can join

Eligibility, any sex, with Glaucoma or Cataract. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to further observe and learn if the SpyGlass Pharma Bimatoprost Implant System / IOL Combination works to treat cataracts and either ocular hypertension or glaucoma. It will also further observe and learn about the safety of the Bimatoprost Implant System / IOL Combination. The main questions it aims to answer are: * Does the Bimatoprost Implant System / IOL Combination continue lower the pressure inside the eye to treat ocular hypertension or glaucoma long term? * Does the Bimatoprost Implant System / IOL Combination continue to correct vision after cataract surgery long term? * What long term medical problems do participants have when treated with the Bimatoprost Implant System / IOL Combination?

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Prospective Pilot Study of Sustained Release Bimatoprost Implant with SpyGlass Intraocular Lens: 3-Year Results.
Tan NE, Katz G, Robles M, Gupta PK, et al · · 2026 · PMID 41621045 · DOI 10.1007/s40123-026-01313-4

Verify or expand the search:

Other recruiting trials for Glaucoma

Currently open trials in the same condition.

NCT07455786 — Modified Trabeculectomy After Failure of Combined Phaco With GATT · NA · recruiting
NCT07298356 — Automated Applanation Tonometry - Updated · NA · recruiting
NCT07217678 — Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use · Phase 4 · recruiting
NCT07145073 — Repetitive Transcranial Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies · NA · recruiting
NCT07209410 — Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanopro · Phase 4 · recruiting

Other SpyGlass Pharma, Inc. trials

Trials by the same sponsor.

NCT07218796 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting
NCT07218783 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting
NCT07154797 — Evaluation of the Safety and Effectiveness of the Bimatoprost Implant System / IOL Combination in Patients With Ocular H · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07154810 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SpyGlass Pharma, Inc.
Last refreshed: 4 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07154810.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing